Press Esc to close

Welcome to Money Morning - Only the News You Can Profit From.


This Says Our Favorite Biotech Is Off to the Races

Shares of a promising biotech we recommended back in February 2013 – jumped as much as 27% to a three-month high of $14.20 yesterday after the company said a new cancer drug met its main goal in a midstage clinical trial.

Its shares backtracked a bit as the day progressed but still closed 17.6% higher for the session. These shares have advanced 361% since we first told you about them. The stock has generated a peak gain of 456%, making it one of the 31 recommendations we’ve made to you that have doubled or better since we launched Private Briefing in August 2011. (More on that later…)

  • Featured Story

    How the Legacy of Steve Jobs Could Haunt Apple

    Now that its iconic founder is truly gone, Apple Inc. (Nasdaq: AAPL) must figure out how to remain true to the legacy of Steve Jobs without getting hamstrung by it.

    It's not as easy as you might think.

    The challenge starts with finding a successor CEO who can carry on the legacy of a founder like Steve Jobs without being intimidated by it.

    "Much like Disney, Apple's founder was the brand. He was their Mickey Mouse, he was their Betty Crocker," corporate governance expert Nell Minow of GovernanceMetrics International told Reuters. "They have to replace him in five different ways."

    That Jobs himself groomed former Chief Operating Officer Tim Cook to follow him as chief executive reduces Apple's risk, but doesn't erase it.

    Companies such as The Walt Disney Co. (NYSE: DIS) and Wal-Mart Stores Inc. (NYSE: WMT) have learned that staying faithful to the ideals of a legendary founder can be fraught with pitfalls. Rigid adherence to old ideas can lead to stagnation, but straying too far from them can undermine what made the company such a huge success.

    To continue reading, please click here...
  • Legacy of Steve Jobs